Mylan's EpiPen Rebate Errors Spark SEC Probe, Investor Suit
The damage Mylan is facing for underpaying Medicaid rebates by misclassifying the EpiPen as a generic drug hasn't ended with Friday's $465 million Justice Department settlement, as the U.S. Securities and...To view the full article, register now.
Already a subscriber? Click here to view full article